Companies › Treadwell Therapeutics
2 active drug programs in 8 registered trials: 5 Phase 2, 3 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CFI-400945 Serine/threonine-protein kinase PLK4 inhibitor | PLK4 | Phase 1 | Acute Myeloid Leukemia; Prostate Cancer; Breast Cancer | – |
| CFI-402257 TTK inhibitor | TTK | Phase 1 | Advanced Solid Tumor; Breast Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03385655 | CFI-400945 | Phase 2 | Prostate Cancer | Oncology | Oct 2024 |
| NCT04730258 | CFI-400945 | Phase 1 | Acute Myeloid Leukemia | Oncology | Jan 2026 |
| NCT05251714 | CFI-402257 | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2026 |
| NCT03624543 | CFI-400945 | Phase 2 | Breast Cancer | Oncology | Nov 2026 |
| NCT03568422 | CFI-402257 | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT04176848 | CFI-400945 | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT05601440 | CFI-402257 | Phase 2 | Breast Cancer | Oncology | Dec 2027 |
| NCT05601440 | CFI-400945 | Phase 2 | Breast Cancer | Oncology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.